Development of Drugs for Antimicrobial-Resistant Pathogens

Add bookmark
Clinicians have noted an association between antimicrobial resistance and antimicrobial use since the introduction of these agents over 50 years ago. The problem of resistance becomes more pressing, however, when organisms acquire resistance mechanisms to multiple antimicrobial agents. Treatment options are limited for some multidrug-resistant organisms. Antimicrobial resistance is a driving force for the need for new antimicrobial agents, especially for these multidrug-resistant pathogens. At the same time, large pharmaceutical companies have indicated that they are devoting fewer resources to antimicrobial drug development.

Upcoming Events

DigIT Pharma 2026 | AI Commercial, Medical & Patient Care

September 9 - 10, 2026

Steigenberger Airport Hotel Berlin, Deutschland

DigIT Pharma 2026 | AI Commercial, Medical & Patient Care

Pharmaceutical Launch Excellence Summit US

September 30 - October 1, 2026

Hyatt Regency Boston Harbor, Boston, US

Pharmaceutical Launch Excellence Summit US

Pharmaceutical Launch Excellence Summit

1 - 3 December, 2026

Novotel Amsterdam City, Netherlands

Pharmaceutical Launch Excellence Summit

SmartLab Exchange Europe

22 - 23 February 2027

Leonardo Royal Hotel Amsterdam, Netherlands

SmartLab Exchange Europe

Latest Webinars

Pharma IQ's Power List 2022: In conversation with pharma's top leaders

2022-10-18

02:00 PM - 03:00 PM BST

Join us to hear from the most influential people in pharma today, as voted for by you

A post-pandemic 3D view of the patient and supply journey

2022-06-01

04:30 PM - 05:30 PM CET

In this panel discussion with experts from 4G Clinical, THREAD Research and World Courier, learn how...

Discover how targeted radiotherapy induced toxicity can be identified with imaging

2022-04-28

01:00 PM - 02:00 PM EST

This Pharma IQ webinar with AIQ explores how AI-assisted analysis of radiological scans enhances the...

Recommended